xzp-3621
Small moleculeexperimental
Clinical trial activity
6 trials · 5 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
2
Phase 3
1
Phase 4
0
Earliest trial started Mar 12, 2019 (NCT05055232)
Timeline
Indications
Mechanism of action
- ALK tyrosine kinase receptorINHIBITOR
ALK inhibitor
ROS1 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05836805 | Phase 1 | May 31, 2023 | Suzhou Medical College, Xuanzhu Biopharmaceutical Co., Ltd. |
| NCT05586568 | Phase 1 | Nov 15, 2022 | Qingdao University, Xuanzhu Biopharmaceutical Co., Ltd. |
| NCT05482087 | Phase 2 | Sep 30, 2022 | Jilin University, Xuanzhu Biopharmaceutical Co., Ltd. |
| NCT05204628 | Phase 3 | Feb 7, 2022 | Jilin University, Xuanzhu Biopharmaceutical Co., Ltd. |
| NCT05034120 | Phase 1 | Sep 30, 2021 | Qingdao University, Xuanzhu Biopharmaceutical Co., Ltd. |
| NCT05055232 | Phase 1 | Mar 12, 2019 | Jiao Tong University, Xuanzhu Biopharmaceutical Co., Ltd. |
Showing 6 of 6 trials
Page 1 / 1
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Xuanzhu Biopharmaceutical Co., Ltd. | For profit | 6 | 6 | 3 | 2019 |
| Jilin University | Academic/Hospital | 2 | 0 | 2 | 2022 |
| Qingdao University | Academic/Hospital | 2 | 0 | 1 | 2021 |
| Jiao Tong University | Academic/Hospital | 1 | 0 | 1 | 2019 |
| Suzhou Medical College | Academic/Hospital | 1 | 0 | 1 | 2023 |
5 organizations
Page 1 / 1